Deal Tracker · Regions

Global (LMICs) pharma licensing deals

11 licensing deals with global (LMIC) scope tracked by EPT (2025–2026). Most active: Gilead Sciences, Arcera Life Sciences, Biocon & Ajanta Pharma. Latest: Innogen Pharmaceuticals → Arcera Life Sciences (Licensing, 19 Nov 2026).

11
deals tracked
9
announced in 2026
$600m
disclosed value (1 deal)
100%
licensing, the top deal type
  • EPT has tracked 11 Global (LMICs) pharma licensing deals (2025–2026), 9 of them announced in 2026.
  • The countries that appear most often are India (4), United States (4), China (2) & UAE (2).
  • Values were disclosed for 1 of 11 deals, totalling $600m; the largest is AriBio → Arcera Life Sciences ($600m, 10 Jun 2025).
  • The most active companies: Gilead Sciences (3), Arcera Life Sciences (2) & Biocon (2).

Most active companies

Gilead Sciences (3) · Arcera Life Sciences (2) · Biocon (2)

Countries involved

India (4) · United States (4) · China (2) · UAE (2) · Brazil (1) · Egypt (1)

Largest disclosed deals

Questions

How many Global (LMICs) pharma licensing deals has EPT tracked?
11 as of 19 Nov 2026, covering 2025–2026; 9 were announced in 2026. The most recent is Innogen Pharmaceuticals → Arcera Life Sciences (Licensing, 19 Nov 2026).
Which companies are most active in Global (LMICs) pharma licensing deals?
Gilead Sciences (3 deals), Arcera Life Sciences (2 deals), Biocon (2 deals).
What is the largest disclosed Global (LMICs) pharma licensing deal?
AriBio → Arcera Life Sciences: $600m (Licensing, 10 Jun 2025). Values are as announced by the parties.
Which countries appear most in Global (LMICs) pharma licensing deals?
India (4), United States (4), China (2), UAE (2), Brazil (1), Egypt (1) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)